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Introduction {#sec005}
============

The emergence of extensively-drug resistant (XDR) Gram negative bacteria (GNB) is increasingly recognized as one of the greatest threat to healthcare \[[@pone.0158740.ref001]\]. Infections caused by these organisms have reported mortality rates of over 50%, and have been associated with increased healthcare costs \[[@pone.0158740.ref002], [@pone.0158740.ref003]\]. This is worsened by the fact that the antibiotic pipeline against GNB has dried out. Consequently, physicians are compelled to resort to 'old' antibiotics such as the polymyxins for the treatment of these infections \[[@pone.0158740.ref001], [@pone.0158740.ref004]\].

In the recent years, there have been an increasing number of physicians employing combination antibiotic therapy against XDR-GNB, in particularly against *Pseudomonas aeruginosa*, *Acinetobacter baumannii* and *Klebsiella pneumoniae* \[[@pone.0158740.ref005]\]. The contentions supporting combination antibiotics are aplenty. When two or more antibiotics are combined, there may be potential additive or even synergistic activity. In addition, combination antibiotics may suppress the emergence of resistant subpopulations, which can otherwise be selectively amplified if only one antibiotic was used \[[@pone.0158740.ref006]\]. On the flipside, irrational use of antibiotic combinations can worsen the already alarming scenario of antimicrobial resistance \[[@pone.0158740.ref006]\]. This has led experts to conclude that if combination antibiotics are employed, the most appropriate combination scheme should leverage on the latest *in vitro* and/or animal infection models, and should be individualized depending on organism, susceptibility profile, infection site and the clinical characteristics of each patient \[[@pone.0158740.ref005], [@pone.0158740.ref007]\].

In view of the current antimicrobial landscape, a prospective *in vitro* antibiotic combination testing (*i*ACT) service, with a rapid turn-around time of 48 hours, was developed. The objective of the *i*ACT service is to guide physicians in the selection of an individualized and rationally optimized combination therapy, taking into account the *in vitro* combination testing results of each strain and the patient's clinical and pharmacokinetic (PK) parameters. In this study, we described the role and feasibility of the *i*ACT service in guiding the selection of individualized and rationally optimized combinations in patients with XDR-GNB infections. In addition, the clinical and microbiological outcomes of patients receiving *i*ACT-guided therapy were described.

Materials and Methods {#sec006}
=====================

Study Design {#sec007}
------------

A retrospective case review was conducted in two Singapore hospitals: Singapore General Hospital, a 1700-bed public hospital and Mount Elizabeth Hospital, a 272-bed private hospital. All adults admitted from 1^st^ April 2009 to 30^th^ June 2014 with microbiologic evidence of XDR-GNB or pan-drug resistant (PDR) GNB isolation causing clinical infections and treated with antibiotic regimen guided by *i*ACT were identified from the service's electronic database and retrospectively reviewed. The use of *i*ACT to guide antibiotic combination selection in these patients was elected by their attending ID physicians as part of their clinical management strategy, out of desperate measures. Patients with infections due to an XDR-/PDR-GNB requiring *i*ACT-guided therapy that were classified as cured, and then developed a subsequent infection after a 90-day period due to a different GNB requiring *i*ACT-guided therapy were analyzed as two different cases. This study was approved by the ethics review board of Singapore General Hospital (2012/818/D) and Mount Elizabeth Hospital (PIEC/2012/038) prior to study initiation. The ethics review board of both institutions waived the need for informed consent as the study involved only a retrospective clinical notes review, and all data collected was analyzed anonymously.

Description of the Prospective *i*ACT Service Workflow {#sec008}
------------------------------------------------------

Before the implementation of the *i*ACT service, the service was introduced to the Infectious Diseases (ID) physicians in the hospitals, to increase awareness of and provide education about the service. Prior to request of the *i*ACT service for a patient with an infection caused by an XDR- or PDR-GNB isolate, the attending ID physician informed each patient (or immediate family member if the patient was incapacitated) of (i) the poor prognostic outcomes of such resistant infections which most or all antibiotics were not effective against, (ii) the nature of the *in vitro* testing method as a last-resort measure to guide treatment, (iii) alternative treatment strategies (e.g. use of polymyxin monotherapy or selecting combinations based on anecdotal experience), iv) the clinical aims of the *i*ACT guided treatment, and (v) the potential toxicities of the treatment. Verbal consent was sought and documented in clinical notes by the attending ID physician before *i*ACT was requested.

The process of the *i*ACT service is detailed in [Fig 1](#pone.0158740.g001){ref-type="fig"}. *In vitro* combination testing was carried out immediately upon request of *i*ACT for an individual patient. Simultaneously, a clinical ID pharmacist would review the patient's clinical records and document all relevant clinical information required to develop rationally optimized combination dosage regimens, based on pharmacokinetics (PK) and pharmacodynamics (PD) principles. At 24h, combinations that were at least bacteriostatic (non-cloudy wells) *in vitro* were identified and fed back as preliminary results to the ID pharmacist. Preliminary recommendations to change antibiotic combinations were made by the ID pharmacist to the attending ID physician, if the initial empiric regimen was not at least bacteriostatic *in vitro*. At 48h, combinations with bactericidal activity *in vitro* were elucidated. Based on these *in vitro* results, the ID pharmacist would select and recommend the most optimal combination(s), with corresponding dosage regimens, to the attending ID physician. Selection was based on the patient's clinical characteristics, site of infection, PK/PD parameter for efficacy of each antibiotic and the probabilities of PK/PD target attainment at infected sites. Clinical ID pharmacist followed-up and reviewed the patient's case notes within 24h post-recommendation, to ensure that the patient was placed on the recommended antibiotic combination regimens.

![Summary of the Work Process of the Prospective *i*ACT Service.\
Combination antibiotic regimens recommended by the *i*ACT service take into account both the *in vitro* bactericidal activity of the combinations and the probability of PK/PD target attainment, and are recommended to the attending ID physician within 48h from request. Abbreviations used in [Fig 1](#pone.0158740.g001){ref-type="fig"}: GNB = Gram-negative bacteria, *i*ACT = *in vitro* antibiotic combination testing, ID = Infectious Diseases, MIC = minimum inhibitory concentration PDR = pan-drug resistant, PK = pharmacokinetic, XDR = extensively-drug resistant.](pone.0158740.g001){#pone.0158740.g001}

Microbiological Methods {#sec009}
-----------------------

Genus identity was determined using VITEK GNI+ cards (bioMérieux, Hazelwood, MO). MICs to various antibiotics were determined using commercial microbroth dilution panels (Trek Diagnostics, UK), and susceptibility was defined as per CLSI \[[@pone.0158740.ref008]\]. All *A*. *baumannii* isolates were screened for *bla*~OXA-23-like~, *bla*~OXA-24-like~, *bla*~OXA-51-like~, and *bla*~OXA-58-like~ genes using a multiplex PCR assay \[[@pone.0158740.ref009]\]. For *P*. *aeruginosa* and *K*. *pneumoniae* isolates, PCR was employed to detect genes encoding commonly acquired metallo-β-lactamases (MBLs) (*bla*~VIM~, *bla*~IMP~, *bla*~SIM~, *bla*~GIM~, *bla*~SPM~) \[[@pone.0158740.ref010], [@pone.0158740.ref011]\]. Analyses of genes encoding ESBLs, AmpC, OXA, KPC and NDM beta-lactamases were also performed for *K*. *pneumoniae* \[[@pone.0158740.ref010], [@pone.0158740.ref011]\]. Changes in porin gene expression (OmpK35 and OmpK36) were determined for *K*. *pneumoniae* using RT-PCR, and presence of efflux pump was determined using efflux pump inhibitor phenyl-arginine-β-naphthylamide (PABN) \[[@pone.0158740.ref008], [@pone.0158740.ref012]\].

*In vitro* combination testing was carried out in clear 96-well microtiter plates, modified from a method by Aaron *et al* \[[@pone.0158740.ref013]\]. Briefly, 100uL of bacterial inoculum was added to a microtiter plate containing 11 antibiotics in single, two-drug and three-drug combinations (100uL of antibiotic solution per well) at clinically relevant unbound concentrations ([Table 1](#pone.0158740.t001){ref-type="table"}) \[[@pone.0158740.ref014]--[@pone.0158740.ref025]\]. This gave approximately 10^5^ CFU/mL (1 × 10^5^--5 × 10^5^ CFU/mL) of bacteria in each well. The wells were covered and incubated at 35°C for 24h. At 24h, bacteriostatic combinations were identified based on presence/absence of visible growth in each well. The contents of each well were then sampled and measured to ensure \<10% loss in volume. The measured contents were centrifuged at 10,000 × g for 15 minutes and the pellet reconstituted to original volume to minimize drug carry-over. Bacterial count was quantified by depositing serial ten-fold dilutions of the sample onto Mueller-Hinton agar plates (BD, Sparks, MD), incubated at 35°C for 24h, and enumerated visually to determine presence of bactericidal activity. The lower limit of detection was 3.9 × 10^2^ CFU/ml.

10.1371/journal.pone.0158740.t001

###### Simulated Antibiotic Dosing Regimens and Corresponding Drug Concentrations.
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  Drugs                                                 Site of Infection Simulated   Simulated Dosing Regimens         Concentration (mg/L)
  ----------------------------------------------------- ----------------------------- --------------------------------- ----------------------
  Amikacin \[[@pone.0158740.ref014]\]                   Plasma                        20 mg/kg every 24h                65
  Levofloxacin \[[@pone.0158740.ref015]\]               Plasma                        750mg every 24h                   8
  Levofloxacin \[[@pone.0158740.ref016]\]               Pulmonary ELF                 750mg every 24h                   20
  Rifampicin \[[@pone.0158740.ref017]\]                 Plasma                        600mg every 12h                   4
  Polymyxin B \[[@pone.0158740.ref018]\]                Plasma                        30,000IU/kg/day                   2
  Tigecycline \[[@pone.0158740.ref019]\]                Tissue                        100mg every 12h                   2
  Cefepime \[[@pone.0158740.ref020]\]                   Plasma                        2g every 8h (infused over 4h)     50
  Meropenem \[[@pone.0158740.ref021]\]                  Plasma                        2g every 8h (infused over 3h)     20
  Doripenem \[[@pone.0158740.ref022]\]                  Plasma                        1g every 8h (infused over 4h)     13
  Imipenem \[[@pone.0158740.ref023]\]                   Plasma                        1g every 6h (infused over 1h)     12.5
  Aztreonam \[[@pone.0158740.ref024]\]                  Plasma                        8g every 24h (infused over 24h)   24
  Piperacillin/ tazobactam \[[@pone.0158740.ref025]\]   Plasma                        4.5g every 6h (infused over 4h)   35/7

Abbreviations used in Table 1: ELF = epithelial lining fluid

Data Collection and Outcome Measures {#sec010}
------------------------------------

All data were extracted from patients' inpatient charts and electronic medical records and documented in a structured form. Baseline characteristics collected included basic demographics, length of stay, presence of co-morbidities, APACHE II score at time of XDR-GNB isolation, history of intensive care unit stay or hospital stay within 3 months of XDR-/PDR-GNB isolation, and history of antibiotic use within 3 months of XDR-/PDR-GNB isolation. Details pertaining to the infection (causative organism, site of infection, date of isolation, *in vitro* susceptibility data and concurrent infections) and antibiotic use (type and duration of antibiotics used) was also collected. The following roles of the *i*ACT service were documented: (i) confirmation of bactericidal activity in the empirically selected regimen (i.e. no change in the empirical regimen) (ii) change in empiric therapy, based on *i*ACT results, or (iii) reduction of number of antibiotics empirically employed in combination, based on *i*ACT results. If the *i*ACT service recommended changes in an empiric therapy, the reasons for the recommendations were investigated. The time from culture isolation to request for *i*ACT service, as well time from request for *i*ACT service to time of provision of preliminary and final recommendations by the *i*ACT service for each case was also documented.

The following patient outcomes were collected: (i) 30-day in-hospital all-cause and infection-related mortality, (ii) clinical response, and (iii) microbiological eradication (assessed only in patients with bloodstream infections as repeat cultures were not routinely taken for other sites). Adverse drugs events potentially attributable to *i*ACT-guided therapy were documented.

Definitions {#sec011}
-----------

XDR and PDR were defined as non-susceptibility to at least one agent in all but two or fewer antibiotic categories and non-susceptibility to all agents in all antimicrobial categories respectively \[[@pone.0158740.ref026]\]. Bacteriostatic activity was defined as the lack of visible growth in the presence of antibiotics at 24h. Bactericidal activity was defined as ≥99.9% decrease in the colony count on subculture of an organism in the presence of antibiotics compared to initial inoculum \[[@pone.0158740.ref013]\]. An empirical regimen was defined as any antimicrobial regimen employed after isolation of XDR-/PDR-GNB but prior to *i*ACT-guided therapy, selected by the attending ID physician based on individual preference, anecdotal experience or recommendations from published literature. Infections were defined in accordance to definitions provided by the Centers for Disease Control and Prevention (CDC) \[[@pone.0158740.ref027]\]. Patients were considered immunocompromised if they had acquired immune deficiency syndrome, were neutropenic (absolute neutrophil count \< 500/mm^3^) or transplant patients on immunosuppressive agents.

Thirty-day in-hospital all-cause and infection-related mortality was defined as all-cause and infection-related death, as determined by the ID physician, that occurred 30 days from isolation of XDR-/PDR-GNB. Clinical response was defined as partial or complete resolution of infection symptoms as determined by the ID physician, irrespective of GNB eradication, while therapeutic failure was defined as worsening at any time or no improvement of clinical conditions by day 14 of therapy as stated by the ID physician. Microbiologic eradication was only assessed for bloodstream infections, and was defined as the clearance of XDR-/PDR-GNB in all follow-up blood cultures. Nephrotoxicity was defined as per RIFLE criteria \[[@pone.0158740.ref028]\].

Data analysis {#sec012}
-------------

Categorical data were presented as numbers and percentages; continuous data were presented as mean ± standard deviation, or median (range), depending on the validity of normality assumption. All data were analyzed using IBM SPSS Statistics 21 (IBM Corp., New York).

Results {#sec013}
=======

Study Population {#sec014}
----------------

From April 2009 to June 2014, 40 patients received *i*ACT-guided therapy. Of these, three patients were excluded as medical records were not available. Two patients developed two episodes of XDR-/PDR-GNB infection more than 90 days apart and were each analyzed as two different cases. Hence, a total of 39 cases were included.

Baseline Demographics and Clinical Features {#sec015}
-------------------------------------------

The clinical features of the patients were summarized in [Table 2](#pone.0158740.t002){ref-type="table"}. More than one-third of the cases (14/39, 35.9%) were immunocompromised, with solid and hematological malignancies being the commonest co-morbidity (16/39, 41.0%). Most cases received antimicrobial agents prior to the XDR-/PDR-GNB infection (37/39, 94.9%); of these, carbapenems were most frequently prescribed (29/39, 74.4%). Bloodstream infection was the predominant infection (14/39, 35.9%), followed by pneumonia (12/39, 30.8%). Of the 14 cases of bloodstream infections, six (42.9%) were secondary to pneumonia, three (21.4%) were associated with catheter-related infections and three (21.4%) were secondary to intra-abdominal infections.

10.1371/journal.pone.0158740.t002

###### Demographics and Clinical Features of Patients Receiving *in Vitro* Combination Antibiotic Testing Guided Therapy (No. of cases = 39).
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  Characteristics                                                          Mean ± s.d. or median (range) or n (%)
  ------------------------------------------------------------------------ ----------------------------------------
  **Basic Demographics**                                                   
  **Mean age ± s.d. (yr.)**                                                56.3 ± 18.3
  **Gender**                                                               
  **Male**                                                                 27 (69.2)
  **Female**                                                               12 (30.8)
  **Median days of stay (range)**                                          54 (10--363)
  **Past Medical History**                                                 
  **Hospitalisation within 3 months**                                      31 (79.5)
  **Intensive care unit stay within 3 months**                             22 (56.4)
  **Invasive intervention within 3 months**                                29 (74.4)
  **XDR or PDR-GNB infection within 3 months**                             16 (41.0)
  **Antibiotic use within 3 months**                                       37 (94.9)
  \- Broad-spectrum beta-lactams                                           14 (35.9)
  \- 3^rd^ and 4^th^ generation cephalosporins                             14 (35.9)
  \- Carbapenems                                                           29 (74.4)
  \- Fluoroquinolones                                                      23 (59.0)
  \- Polymyxins (B or E)                                                   11 (28.2)
  **Co-morbidities**                                                       
  **No comorbidities**                                                     4 (10.3)
  **Ischemic heart disease**                                               6 (15.4)
  **Congestive heart failure**                                             6 (15.4)
  **Chronic kidney disease**                                               9 (23.1)
  **Type II diabetes mellitus**                                            15 (38.5)
  **Hepatic disease**                                                      5 (12.8)
  **Solid and hematological malignancy**                                   16 (41.0)
  **Immunocompromised status**                                             14 (35.9)
  **Median Charlson's comorbidity index (range)**                          5 (0--14)
  **Type of Infection**                                                    
  **Bloodstream infection**                                                14 (35.9)
  \- Secondary to respiratory source                                       6 (15.4)
  \- Secondary to line infection                                           3 (7.7)
  \- Secondary to complicated intra-abdominal infection                    3 (7.7)
  \- Other bloodstream infections [^a^](#t002fn001){ref-type="table-fn"}   2 (15.4)
  **Hospital/ ventilator-associated pneumonia**                            12 (30.8)
  **Complicated intra-abdominal infection**                                3 (7.7)
  **Osteomyelitis**                                                        5 (12.8)
  **Others Infections** [^**b**^](#t002fn002){ref-type="table-fn"}         5 (12.8)
  **Patients with concurrent infections**                                  10 (25.6)
  **Median APACHE II score at time of infection (range)**                  13 (4--31)

^a^ Other causes of bloodstream infections include, skin and soft tissue infections (n = 1), and complicated urinary tract infection (n = 1).

^b^ Other infections include complicated urinary tract infection (n = 2), skin and soft tissue infections (n = 2) and mastoiditis (n = 1)

Abbreviations used in Table 2: APACHE II = Acute Physiology and Chronic Health Evaluation II, GNB = Gram-negative bacteria, PDR = pan-drug resistant, XDR = extensively-drug resistant

The XDR- or PDR-GNB pathogens {#sec016}
-----------------------------

[Table 3](#pone.0158740.t003){ref-type="table"} detailed the resistance mechanisms and *in vitro* susceptibilities of the pathogens. Of the 39 isolates (20 *P*. *aeruginosa*, 13 *A*. *baumannii* and 6 *K*. *pneumoniae*), 31 (79.5%) were XDR and 8 (20.5%) were PDR (four *P*. *aeruginosa*, three *A*. *baumannii* and one *K*. *pneumoniae*). Of the 31 XDR isolates, 19 (61.3%), were sensitive to polymyxin B only. All *A*. *baumannii* harbored *bla*~OXA23~ and *bla*~OXA51~ carbapenemase genes, while 60% (12/20) of the *P*. *aeruginosa* isolates harbored genes encoding MBLs (3 *bla*~VIM~, 9 *bla*~IMP~). A large variety of mechanisms mediating carbapenem resistance was observed for *K*. *pneumoniae* isolates. Amongst the six *K*. *pneumoniae* isolates, four (66.7%) *K*. *pneumoniae* isolates harbored both genes encoding NDM as well as OXA-181 carbapenemases. Of these, one isolate also demonstrated reduction in porin gene expression, while another had presence of efflux pump as determined by phenotypic methods.

10.1371/journal.pone.0158740.t003

###### Description of *In Vitro* Antimicrobial Susceptibility and MIC ranges of XDR- or PDR-GNB (20 Strains of *Pseudomonas aeruginosa*, 13 Strains of *Acinetobacter baumannii* and 6 Strains of *Klebsiella pneumoniae*).
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                                *P*. *aeruginosa* (n = 20)   *A*. *baumannii* (n = 13)   *K pneumoniae* (n = 6)                                                                                              
  ----------------------------- ---------------------------- --------------------------- ------------------------------------------------- ---------------- ------------------------------------------------ ----------
  **Ampicillin/sulbactam**      ND                           ND                          13 (100)                                          32/16--≥128/64   6 (100)                                          ≥128/64
  **Piperacillin/tazobactam**   20 (100)                     32/4--≥256/4                13 (100)                                          ≥256/4           6 (100)                                          ≥256/4
  **Cefepime**                  20 (100)                     32--≥256                    13 (100)                                          ≥64              6 (100)                                          ≥64
  **Imipenem**                  19 (95.0)                    2--≥64                      13 (100)                                          32--≥64          6 (100)                                          4--≥64
  **Meropenem**                 20 (100)                     4--≥64                      13 (100)                                          32--≥64          6 (100)                                          4--≥64
  **Doripenem**                 20 (100)                     4--≥64                      13 (100)                                          16--≥64          6 (100)                                          4--≥64
  **Aztreonam**                 18 (90.0)                    8--≥128                     NA[^a^](#t003fn001){ref-type="table-fn"}          16--≥64          6 (100)                                          ≥128
  **Levofloxacin**              20 (100)                     32--≥64                     13 (100)                                          8--≥64           6 (100)                                          8--≥64
  **Tigecycline**               ND                           ND                          10 (76.9)[^b^](#t003fn002){ref-type="table-fn"}   0.5--32          4 (66.7)[^b^](#t003fn002){ref-type="table-fn"}   0.5--≥64
  **Rifampicin**                ND                           ND                          NA[^a^](#t003fn001){ref-type="table-fn"}          2--≥64           NA[^a^](#t003fn001){ref-type="table-fn"}         8--≥64
  **Gentamicin**                19 (95.0)                    4--≥64                      13 (100)                                          ≥64              5 (83.3)                                         0.5--≥64
  **Amikacin**                  16 (80.0)                    1--≥128                     13 (100)                                          ≥128             5 (83.3)                                         2--≥64
  **Polymyxin B**               4 (20.0)                     1--8                        3 (23.1)                                          0.5--8           NA[^a^](#t003fn001){ref-type="table-fn"}         0.5--64

^a^ No breakpoints recommended by Clinical and Laboratory Standards Institute (CLSI)

^b^ Susceptibility defined as ≤2mg/L, according to the Food and Drug Administration (FDA) breakpoints for Enterobacteriaceae

Abbreviations used in Table 3: GNB = Gram negative bacteria, I = intermediate, MIC = minimum inhibitory concentration, NA = not applicable, ND = not done, PDR = pan-drug resistant, R = resistant, XDR = extensively-drug resistant

Antibiotic Combinations and Role of the *i*ACT Combination Testing Service {#sec017}
--------------------------------------------------------------------------

A delay between the time of culture isolation and request for *i*ACT service (median: 4 days; range: 2--47 days) was observed. This delay was attributed to the fact that several ID physicians elected to use empirically selected combinations first upon culture isolation, and only requested for *i*ACT service after the patients failed to respond to the empirically selected combinations. Upon request and isolate receipt, the *i*ACT service provided all preliminary results (based on well turbidity) to the ID physicians within 24h. All final *i*ACT recommendations were provided to the ID physicians within 48h.

Prior to *i*ACT-guided therapy, most cases were empirically prescribed combination therapy (35/59, 89.7%) ([Table 4](#pone.0158740.t004){ref-type="table"}). More than half (21/39, 53.8%) of the cases were prescribed three or more antibiotics in combination empirically. Against *P*. *aeruginosa*, polymyxin B plus a carbapenem plus fluoroquinolones or aminoglycosides were the most common three-antibiotic regimen prescribed empirically, while against *A*. *baumannii*, polymyxin B plus a carbapenem plus tigecycline or rifampicin were the most common three-antibiotic regimen prescribed empirically. Empiric therapy was changed by the *i*ACT service in 21 (53.9%) cases ([Table 5](#pone.0158740.t005){ref-type="table"})--the commonest reasons for change was that empiric antibiotic regimens were not bactericidal *in vitro* (14/21, 66.7%), or that a more appropriate combination regimen, based on the probabilities of PK/PD target attainment at infected sites, could be used (4/21, 19.0%). In 7 (17.9%) patients, the number of antibiotics used in combination empirically was reduced. The *i*ACT service recommended dose changes in 8 (20.5%) patients; most recommendations involved increasing doses or prolonging infusion time to optimize probability of PK/PD target attainment.

10.1371/journal.pone.0158740.t004

###### Summary of Antibiotic Therapy Prescribed (a) Empirically, and (b) Based on Recommendations from the *i*ACT Service.
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  --------------------------------------------------------------------------------------------- ---------------------------- -------------------------------- ------------------------------- -------------------------------
  **Antibiotic Therapy prescribed Empirically (%)**[^**a**^](#t004fn001){ref-type="table-fn"}   **All organisms (n = 39)**   ***P*. *aeruginosa* (n = 20)**   ***A*. *baumannii* (n = 13)**   ***K*. *pneumoniae* (n = 6)**
  **Antibiotic monotherapy**                                                                    4 (10.3)                     3 (15.0)                         1 (7.7)                         0 (0)
  **Two-antibiotic in combination**                                                             14 (35.9)                    7 (35.0)                         5 (38.5)                        2 (33.3)
  \- Polymyxin B + carbapenem                                                                   5 (12.8)                     4 (20.0)                         0 (0)                           1 (16.7)
  \- Other polymyxin B-based two-antibiotic combinations                                        6 (15.4)                     2 (10.0)                         4 (30.8)                        1 (16.7)
  \- Non-polymyxin B based two-antibiotic combinations                                          3 (7.7)                      1 (5.0)                          1 (7.7)                         0 (0)
  **Three antibiotics in combination**                                                          16 (41.0)                    8 (40.0)                         5 (38.5)                        3 (50.0)
  \- Polymyxin B-based three-antibiotic combinations                                            14 (35.9)                    7 (35.0)                         4 (30.8)                        3 (50.0)
  \- Non-polymyxin B based three-antibiotic combinations                                        2 (5.1)                      1 (5.0)                          1 (7.7)                         0 (0)
  **≥Four antibiotics in combination**                                                          5 (12.8)                     2 (10.0)                         2 (15.4)                        1 (16.7)
  **Antibiotic Therapy prescribed based on Recommendations from the *i*ACT Service (%)**        **All organisms (n = 39)**   ***P*. *aeruginosa* (n = 20)**   ***A*. *baumannii* (n = 13)**   ***K*. *pneumoniae* (n = 6)**
  **Two-antibiotic in combination**                                                             24 (61.5)                    11 (55.0)                        10 (76.9)                       3 (50.0)
  \- Polymyxin B + carbapenem                                                                   10 (25.6)                    2 (10.0)                         7 (53.8)                        1 (16.7)
  \- Polymyxin B + rifampicin                                                                   1 (2.6)                      0 (0)                            1 (7.7)                         0 (0)
  \- Polymyxin B + tigecycline                                                                  1 (2.6)                      0 (0)                            1 (7.7)                         0 (0)
  \- Other polymyxin B based two-antibiotic combinations                                        7 (17.9)                     5 (25.0)                         0 (0)                           2 (33.3)
  \- Non-polymyxin B two-antibiotic combinations                                                5 (12.8)                     4 (20.0)                         1 (7.7)                         0 (0)
  **Three antibiotics in combination**                                                          15 (38.5)                    9 (45.0)                         3 (23.1)                        3 (50.0)
  \- Polymyxin B-based three-antibiotic combinations                                            15 (38.5)                    9 (45.0)                         3 (23.1)                        3 (50.0)
  --------------------------------------------------------------------------------------------- ---------------------------- -------------------------------- ------------------------------- -------------------------------

^a^ Antibiotic therapy prescribed by the attending physician prior *to in vitro* combination testing were based on personal preference, physician's past experience or published literature

Abbreviations used in Table 4: *i*ACT = *in vitro* antibiotic combination testing

10.1371/journal.pone.0158740.t005

###### Role of Prospective *i*ACT Service in Guiding Antibiotic Combination Therapy.
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  Role of *i*ACT Service                                                Role of Prospective *i*ACT Service (%)
  --------------------------------------------------------------------- ----------------------------------------
  **Confirmation of empiric therapy**                                   11 (28.2)
  **Change in empiric therapy**                                         21 (53.9)
  \- Initial antibiotic regimen not bactericidal *in vitro*             14 (35.9)
  \- Need for polymyxin-sparing regimen                                 3 (7.7)
  \- Optimize therapy based on PK/PD                                    4 (10.3)
  **Reduction of no. of antibiotics used empirically in combination**   7 (17.9)
  **Change in doses or dosing regimen**                                 8 (20.5)

Abbreviations used in [Table 4](#pone.0158740.t004){ref-type="table"}: *i*ACT = *in vitro* antibiotic combination testing, PK/PD = pharmacokinetic and pharmacodynamic parameters

Polymyxin B-based two- or three-drug combinations were the commonest *i*ACT-guided therapy prescribed (33/39, 84.6%). Nebulized colistin was initiated in all patients with pneumonia who were prescribed intravenous polymyxin B (16/39, 41.0%). The most common combination recommended against *A*. *baumannii* infections were polymyxin B plus a carbapenem (7/13, 53.8%). Against the *P*. *aeruginosa* isolates, polymyxin B plus carbapenem plus aminoglycosides were most commonly recommended (5/20, 25.0%). Antibiotic combination regimens recommended for *K*. *pneumoniae* infections were highly strain-specific; no single regimen was universally effective against all *K*. *pneumoniae* strains.

Clinical and Microbiological Outcomes {#sec018}
-------------------------------------

The outcomes according to infection type and responsible pathogen are detailed in [Table 6](#pone.0158740.t006){ref-type="table"}. Six (15.4%) cases died due to infection; of these, five were critically ill at the time of initiation of *i*ACT-guided therapy (APACHE II score at time of *i*ACT-guided therapy ranged from 17--30 in these patients). For the remaining patient, the initial episode of ventilator-associated pneumonia resolved upon *i*ACT-guided therapy; however, the patient developed a new episode of sepsis within 30 days and died. Clinical response (cure or improvement) was observed in 32 (82.1%) patients. Of note, clinical response was observed for all seven patients in whom the number of antibiotics used in combination was reduced. Out of the 14 patients with bloodstream infections, 11 (78.6%) had documented microbiological eradication. Thirteen (33.3%) patients developed adverse drugs events: 10 (25.6%) developed nephrotoxicity likely secondary to polymyxin B (n = 8) or polymyxin B plus amikacin (n = 2), two (5.1%) developed non-*Clostridium difficile*-associated-diarrhea, and one (2.6%) developed confusion secondary to levofloxacin. No death related to the adverse events was observed. Adverse events resolved in all patients who survived (7/10, 70.0%).

10.1371/journal.pone.0158740.t006

###### 30-day In-Hospital All-Cause and Infection-Related Mortality, Clinical Response, and Microbiological Eradication Associated with the Type of Infections and Responsible Pathogens.

![](pone.0158740.t006){#pone.0158740.t006g}

  Type of infection or pathogen responsible                                                     No. with outcome of interest/ total[^a^](#t006fn001){ref-type="table-fn"} (%)   No. without outcome of interest/ total[^a^](#t006fn001){ref-type="table-fn"} (%)
  --------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------- ----------------------------------------------------------------------------------
  **30-day in-hospital all-cause mortality**                                                                                                                                    
  **All infections and pathogens**                                                              8/39 (20.5)                                                                     31/39 (79.5)
  **Based on type of infections**                                                                                                                                               
  \- Hospital/ ventilator-associated pneumonia                                                  4/12 (33.3)                                                                     8/12 (66.7)
  \- Bloodstream infections                                                                     3/14 (21.4)                                                                     11/14 (78.6)
  \- Complicated intra-abdominal infections                                                     0/3 (0)                                                                         3/3 (100)
  \- Osteomyelitis                                                                              0/5 (0)                                                                         5/5 (100)
  \- Other infections[^b^](#t006fn002){ref-type="table-fn"}                                     1/5 (20.0)                                                                      4/5 (80.0)
  **Based on infecting pathogen:**                                                                                                                                              
  *- P*. *aeruginosa*                                                                           5/20 (25.0)                                                                     15/20 (75.0)
  *- A*. *baumannii*                                                                            3/13 (23.1)                                                                     10/13 (76.9)
  *- K*. *pneumoniae*                                                                           0/6 (0)                                                                         6/6 (100)
  **30-day in-hospital infection-related mortality**                                                                                                                            
  **All infections and pathogens**                                                              6/39 (15.4)                                                                     33/39 (84.6)
  **Type of infections**                                                                                                                                                        
  \- Hospital/ ventilator-associated pneumonia                                                  4/12 (33.3)                                                                     8/12 (66.7)
  \- Bloodstream infections                                                                     1/14 (7.1)                                                                      13/14 (92.9)
  \- Complicated intra-abdominal infections                                                     0/3 (0)                                                                         3/3 (100)
  \- Osteomyelitis                                                                              0/5 (0)                                                                         5/5 (100)
  \- Other infections[^b^](#t006fn002){ref-type="table-fn"}                                     1/5 (20.0)                                                                      4/5 (80.0)
  **Pathogen responsible**                                                                                                                                                      
  *- P*. *aeruginosa*                                                                           4/20 (20.0)                                                                     16/20 (80.0)
  *- A*. *baumannii*                                                                            2/13 (15.4)                                                                     11/13 (84.6)
  *- K*. *pneumoniae*                                                                           0/6 (0)                                                                         6/6 (0)
  **Clinical response at end of therapy**                                                                                                                                       
  **All infections and pathogens**                                                              **32/39 (82.1)**                                                                **7/39 (17.9)**
  **Type of infections**                                                                                                                                                        
  \- Hospital/ ventilator-associated pneumonia                                                  8/12 (66.7)                                                                     4/12 (33.3)
  \- Bloodstream infections                                                                     12/14 (85.7)                                                                    2/14 (14.3)
  \- Complicated intra-abdominal infections                                                     3/3 (100)                                                                       0/3 (0)
  \- Osteomyelitis                                                                              5/5 (100)                                                                       0/5 (0)
  \- Other infections[^b^](#t006fn002){ref-type="table-fn"}                                     4/5 (80.0)                                                                      1/5 (20.0)
  **Pathogen responsible**                                                                                                                                                      
  *- P*. *aeruginosa*                                                                           16/20 (80.0)                                                                    4/20 (25.0)
  *- A*. *baumannii*                                                                            11/13 (84.6)                                                                    2/13 (15.4)
  *- K*. *pneumoniae*                                                                           6/6 (100)                                                                       0/6 (0)
  **Microbiological eradication at end of therapy**[^**c**^](#t006fn003){ref-type="table-fn"}                                                                                   
  **Type of infections**                                                                                                                                                        
  \- Bloodstream infections                                                                     11/14 (78.6)                                                                    3/14 (21.4)
  **Pathogen responsible**                                                                                                                                                      
  *- P*. *aeruginosa*                                                                           3/5 (60.0)                                                                      2/5 (40.0)
  *- A*. *baumannii*                                                                            5/6 (83.3)                                                                      1/6 (16.7)
  *- K*. *pneumoniae*                                                                           3/3 (100)                                                                       0/3 (0)

^a^ The denominator reflects the number of patients with the stated infection or infecting pathogen.

^b^ Other infections include complicated urinary tract infection, skin and soft tissue infections and mastoiditis.

^c^ Microbiological eradication was only assessed for patients with bloodstream infections (n = 14).

Discussion {#sec019}
==========

This study explored the role and feasibility of a prospective *in vitro* combination testing service in our local setting. We found that the *i*ACT service could provide individualized recommendations for the most optimal combination within a rapid turn-around time of 48h and provided an attractive alternative to selecting antibiotic combinations merely based on individual physician's anecdotal experience. In addition, we observed promising rates of clinical response and infection-related mortality in patients prescribed *i*ACT-guided combination therapy.

The emergence of XDR-GNB worldwide and in Singapore has caused several paradigm shifts in antibiotic therapy \[[@pone.0158740.ref001]\]. In addition to the revival of old antibiotics, combination therapy has been increasingly accepted as common practice in the treatment of XDR-GNB infections \[[@pone.0158740.ref006]\]. Unfortunately, choosing an effective combination can be difficult due to several reasons. Traditional single-antibiotic susceptibility results have limited utility in the guiding the selection of combination therapy against XDR-/PDR-GNB. As a result, the vast majority of combinations can only be chosen empirically, based on individual's physician's preference \[[@pone.0158740.ref007]\]. However, selecting a combination based on anecdotal experience is often counter-productive in our local setting, as resistance is often mediated by more than one mechanism, resulting in strain-specific differences in combinations that are bactericidal, even within a single species. Hence, selecting combinations based merely on anecdotal experience can result in the prescription of an ineffective combination, potentially compromising patient outcomes. In addition, such irrational use of combination antibiotics may perpetuate the cycle of increasing resistance, as well as subject the patients to increased risk of adverse events \[[@pone.0158740.ref007]\].

The prospective *i*ACT service was developed to guide physicians in managing patients with XDR-/PDR-GNB infections. The service employed a bench-to-bedside approach to design rationally optimized and individualized antibiotic combination regimens based on PK and PD principles. An *in vitro* combination testing method, designed to systematically test 80 two- and three-drug combinations within 48h, was first employed to prospectively determine the bactericidal activity of antibiotic combinations *in vitro* against individual strains \[[@pone.0158740.ref013]\]. Leveraging on the *in vitro* results, clinical ID pharmacists then selected the most appropriate antibiotic combination, taking into consideration all relevant PK parameters, such as the patient's comorbidity status, patient's renal and hepatic function and distribution of the antibiotics to the site of infection. Recommendations made by the ID pharmacists do not merely consist of specific antibiotic combinations; instead, individualized dosage regimens (doses, route and infusion time), optimized to achieve PK/PD targets at the site of infection, were recommended to best maximize efficacy and decrease risk of resistance emergence.

In this study, we observed that most physicians empirically prescribed combination therapy prior to *i*ACT-guided therapy, selected based on previously published literature or based on individual physicians' past experience \[[@pone.0158740.ref009], [@pone.0158740.ref029]\]. Unfortunately, of these, less than half of these empirically prescribed combinations were found to be bactericidal *in vitro*, highlighting the inadequacy of selecting combinations based on anecdotal experience in our local setting. Considerable delay was noted between isolation of XDR-GNB and request for *i*ACT service. This is mainly attributable to the fact that the *i*ACT service was not mandatory; as such, several physicians opted to request for *i*ACT service only after patients failed to respond to the initial empiric combination. This can result in the potential benefits conferred by the *i*ACT-guided combination therapy being negated by the delay in time to appropriate therapy, especially in the critically-ill patients. Moving forward, continued education will be required to reinforce the importance of early referral to the *i*ACT service, to ensure the timely prescription of the most appropriate antibiotic combinations.

Our *i*ACT service employed an *in vitro* combination testing method to guide the selection of antibiotic combinations against each XDR-GNB strain. This can reveal any increased or decreased killing brought about by potential synergy (e.g. mechanistic or subpopulation synergy) or antagonism respectively when two or more antibiotics are combined \[[@pone.0158740.ref030]\]. In addition to guiding the selection of individualized and rationally optimized combinations in patients with XDR-GNB infections, we found that the *i*ACT service potentially provided other functionalities. In 20% of the patients, the *i*ACT service reduced the number of antibiotics initially used in combination. This suggests that the *i*ACT service plays a role in antimicrobial stewardship, reducing unnecessary or indiscreet antibiotic use.

Overall, we observed an all-cause mortality rate of 21% in our study patients, which compared favorably to mortality rates reported in other studies. In a study by Crusio *et al*, all-cause in-hospital mortality was 47% in patients infected with carbapenem-resistant GNB and treated with polymyxin B-based combinations \[[@pone.0158740.ref031]\]. Similar rates of 30-day all-cause mortality (43%) were observed in study by Durante-Mangoni *et al* \[[@pone.0158740.ref032]\]. We acknowledged that the observed differences in observed mortality rates may be contributed by a multitude of factors, such as differences in severity of illness. However, it must be highlighted that the combinations employed for patients in these previously published studies were selected based on anecdotal experience or based on results from previously published studies, and not based on strain-specific *in vitro* combination testing results as per our study. More than 80% of patients receiving *i*ACT guided combination therapy had documented clinical response in our study. Of note, clinical response was observed for all patients, in whom the number of combination antibiotics used empirically was reduced, suggesting that reducing the number of antibiotics in combination based on *i*ACT did not compromise patients' outcomes.

To date, only one study explored the use of prospective combination testing to guide therapy in non-cystic fibrosis patients. In a case series by Nakamura *et al*, a break-point checkerboard plate technique was employed to guide combination selection against multi-drug resistant *P*. *aeruginosa* \[[@pone.0158740.ref033]\]. The study, however, selected combinations based solely on the results of *in vitro* testing, and did not take into account patient's PK/PD parameters. Furthermore, the study only reported patients with clinical improvement. In contrast, our study assessed all patients whose antibiotic regimen was prospectively guided by *i*ACT service; in addition to *in vitro* testing, PK/PD principles were applied as the basis for rational selection of antibiotic combinations and dosing regimens.

Despite our promising findings, this study had several limitations. While we observed promising rates of clinical success and infection-related mortality in our study, we acknowledged that the study was not designed to examine outcomes, as no control group was employed for outcome comparison. Hence, no conclusion could be made with regards to the impact of the *i*ACT service on patient outcomes. Moving forward, a randomized trial will be required to fully evaluate the utility of the service in improving patient outcomes. In addition, given that the *i*ACT service was not mandatory, physicians may be inclined to request *i*ACT service only for certain subset of patients with XDR-GNB infections (e.g. those who did not respond to the initial empiric therapy), which can result in selection bias.

Conclusion {#sec020}
==========

We found that the prospective *i*ACT service can be feasibly implemented to guide the timely selection of rationally optimized combination regimens against XDRGNB, and played an additional role in reducing indiscreet antibiotic use. While further randomized trials will be required to fully evaluate the utility of the service, it is hoped that the prospective *i*ACT service can be continually employed to guide the rational selection of antibiotic combinations, and to reduce indiscreet use of antibiotic combinations.
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